14.2 Obstructive Sleep Apnea Studies in Adults with Obesity Overview of Study 5 and Study 6 The efficacy of ZEPBOUND for moderate to severe obstructive sleep apnea (OSA) (apnea-hypopnea index [AHI] 15) in patients with obesity (BMI 30 kg/m2) was evaluated in a master protocol clinical trial (NCT05412004) that included two randomized, double-blind, placebo-controlled trials (Study 5 and Study 6) of 52 weeks duration
If you swallow it too early, the potent medication gets sent to your stomach, where digestive acids can degrade it and significantly reduce its bioavailability and effectiveness
Research shows that in senescent cells, p53 levels are maintained low through ubiquitination while its pro-apoptotic activity is repressed through nuclear segregation by FOXO4. The peptide's competitive inhibition restores p53 activity by promoting nuclear exclusion, allowing p53 to execute its pro-apoptotic program and eliminate senescent cells through targeted pathway activation
This not only helps patients navigate the process but also demonstrates the clinics commitment to patient care
Coverage varies, but Klinic will help you determine your specific eligibility and costs
